Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and…
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY
- Promotore
- Fondazione GONO Onlus
- Acronimo
- TRINITY
- Struttura
- Oncologia
- Sperimentatore principale
- Traverso Elena
- Stato arruolamento
- In attesa di arruolamento